Wellcome Trust

Cultivarium develops open-source tools for life scientists to expand access to novel microorganisms and research.

RenBio develops antibody-based therapeutic solutions for the treatment of cancer and inflammatory diseases. RenBio's proprietary MYO technology involves in the development of antibody therapeutic that helps in treating rare diseases, viral infections, autoimmune diseases, and more by using DNA blueprint and antibody factory.

Vaxxas is a biotechnology company based in Brisbane, Australia, that specializes in developing a needle-free vaccination technology aimed at transforming vaccine delivery. The company's innovative system employs an array of vaccine-coated micro projections that penetrate the outer layers of the skin when applied with a specialized applicator device. This approach allows for direct deposition of vaccines among a dense concentration of immune cells in the skin. Additionally, Vaxxas utilizes proprietary dry-coating technology to minimize or eliminate the need for refrigeration during the storage and transport of vaccines, thereby alleviating the logistical challenges associated with maintaining the cold chain. Founded in 2011, Vaxxas aims to enhance global vaccination efforts through its novel delivery system.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

data.org seeks to democratize and reimagine the use of data science to tackle society’s greatest challenges and improve lives across the globe. Our current initiatives aim to advance inclusive growth, build capacity, mitigate and adapt to climate change and fight pandemics.

Generate Capital, Inc. is a specialty finance company that focuses on building, owning, and operating sustainable infrastructure assets across various sectors, including energy storage, solar energy, energy efficiency, and water resources. Founded in 2014 and headquartered in San Francisco, the company provides a range of financial services such as asset-backed lending, project finance, and tailored financing solutions. Generate partners with project developers, technology manufacturers, and contractors to facilitate the deployment of renewable energy and other sustainable resources. By financing scalable businesses in these sectors, Generate aims to support clients in generating revenue and advancing the resource revolution.

Oxitec Limited is a biotechnology company based in Oxford, United Kingdom, focused on developing innovative solutions for controlling insect pests that transmit diseases and damage crops. Founded in 2002, the company employs proprietary genetic technology to enhance the effectiveness and safety of pest control methods, particularly the Sterile Insect Technique (SIT). Oxitec's products include various genetically modified strains of insects, such as the Aedes aegypti mosquito and the Diamondback moth, designed to reduce populations of disease-carrying and crop-damaging species. These strains are engineered for specific environments in Asia and Latin America and include features like female lethality and fluorescent markers for easy identification. With a mosquito production facility in Brazil, Oxitec aims to provide sustainable, non-toxic alternatives for pest management, thereby contributing to global health and agricultural productivity while minimizing environmental impact.

TAE Technologies, Inc. is a company focused on developing clean fusion energy through advanced particle accelerator and plasma physics. Founded in 1998 and headquartered in Foothill Ranch, California, with an additional office in Rancho Santa Margarita, TAE Technologies aims to create a new source of energy derived from natural processes that generates no harmful byproducts. With over two decades of research, the company is dedicated to commercializing safe and cost-effective fusion power solutions. TAE Technologies also contributes to advancements in power management, electric mobility, and life sciences, addressing the global energy demand while promoting sustainable and carbon-free energy alternatives.

ThinkSono is a company at the cutting edge of medicine and technology.

Mission: We predict life-threatening medical events so that patients and healthcare providers can prevent them. Vision: Empowering all people to enjoy longer, healthier lives.

Verne Global, Inc. is a provider of computing solutions specializing in colocation and high-performance computing (HPC)-as-a-Service. Founded in 2006 and based in Arlington, Virginia, the company operates an environmentally-friendly data center campus in Keflavik, Iceland, which has been operational since 2012. This 45-acre facility, built on the site of a former NATO Command Center, was designed to address the challenges of rising power costs and carbon emissions in the data center industry. By utilizing renewable energy sources, including geothermal and hydroelectric power, Verne Global offers a competitively priced, carbon-neutral energy solution. The strategic location of the campus allows global clients to benefit from affordable power while ensuring reliability, making it an appealing option for industries such as artificial intelligence, earth sciences, engineering, financial services, life sciences, and scientific research. Verne Global operates as a subsidiary of Verne Holdings ehf.

Mologic Ltd. is a UK-based company specializing in the development of diagnostic products primarily for the research market. Founded in 2003 by a father-son team, the company is committed to enhancing patient care and advancing research in various fields, including clinical research, diagnostic development, and wound care. Mologic offers a range of diagnostic tools, such as lateral flow kits for measuring Alpha-1 antitrypsin and desmosine in urine, as well as fMLP assay kits for detecting fMLP in human urine. In addition to its product offerings, the company provides services in assay and reagent development, clinical evaluation studies, and the creation of high-performance antibodies for challenging targets. Mologic aims to make significant contributions to healthcare and education through its innovative research and development efforts.

Prokarium Limited is a biopharmaceutical company based in London, United Kingdom, specializing in the development of vaccination and cancer immunotherapy solutions utilizing synthetic biology. The company’s product pipeline includes Vaxonella, which is designed to enhance immune responses through its unique delivery method involving micro fold cells in the small intestine. Prokarium is also working on vaccines targeting Clostridium difficile, Chlamydia trachomatis, plague, and enteric fever. With a focus on microbial immunotherapy, Prokarium aims to revolutionize cancer treatment, particularly in bladder cancer, by creating immune-driven, long-lasting antitumor effects. Founded in 2007, Prokarium is committed to advancing the field of immuno-oncology through innovative approaches that harness the power of synthetic biology.

Kineta, Inc. is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing immunology-based therapies for various diseases, including oncology, neuroscience, and virology. The company is advancing several innovative treatments, such as KCP-506, an antagonist for chronic pain, and LHF-535, an oral antiviral therapy effective against Lassa virus and other arenaviruses. Additionally, Kineta is working on drug development programs targeting RIG-I and VISTA to enhance immune responses against cancer. Founded in 2007, the company has established strategic partnerships with major corporations in the pharmaceutical industry to further its research and development efforts.

Integrated BioTherapeutics is a biotechnology company that focuses on discovering novel vaccines and therapeutics for emerging infectious diseases. Its antiviral pipeline includes unique pan-filovirus antibody candidates, vaccines, and a variety of other product candidates for emerging viruses.

Karuna Therapeutics is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, dedicated to developing innovative therapies for neuropsychiatric disorders and pain. Its lead product candidate, KarXT, is an oral modulator that has completed a Phase II clinical trial for treating acute psychosis in schizophrenia patients and is undergoing a Phase Ib clinical trial for various central nervous system disorders, including cognitive and negative symptoms of schizophrenia, Alzheimer’s, and dementia-related psychosis. The company is also developing additional muscarinic-targeted drug candidates to address unmet medical needs in these areas. Founded in 2009, Karuna Therapeutics has established partnerships with organizations such as Eli Lilly and Company and PureTech Health LLC, focusing on advancing its drug discovery efforts through collaborations with Charles River Laboratories and PsychoGenics Inc.

Karuna Therapeutics is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, dedicated to developing innovative therapies for neuropsychiatric disorders and pain. Its lead product candidate, KarXT, is an oral modulator that has completed a Phase II clinical trial for treating acute psychosis in schizophrenia patients and is undergoing a Phase Ib clinical trial for various central nervous system disorders, including cognitive and negative symptoms of schizophrenia, Alzheimer’s, and dementia-related psychosis. The company is also developing additional muscarinic-targeted drug candidates to address unmet medical needs in these areas. Founded in 2009, Karuna Therapeutics has established partnerships with organizations such as Eli Lilly and Company and PureTech Health LLC, focusing on advancing its drug discovery efforts through collaborations with Charles River Laboratories and PsychoGenics Inc.

Karuna Therapeutics is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, dedicated to developing innovative therapies for neuropsychiatric disorders and pain. Its lead product candidate, KarXT, is an oral modulator that has completed a Phase II clinical trial for treating acute psychosis in schizophrenia patients and is undergoing a Phase Ib clinical trial for various central nervous system disorders, including cognitive and negative symptoms of schizophrenia, Alzheimer’s, and dementia-related psychosis. The company is also developing additional muscarinic-targeted drug candidates to address unmet medical needs in these areas. Founded in 2009, Karuna Therapeutics has established partnerships with organizations such as Eli Lilly and Company and PureTech Health LLC, focusing on advancing its drug discovery efforts through collaborations with Charles River Laboratories and PsychoGenics Inc.

PredictImmune Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on developing prognostic tests for immune-mediated inflammatory diseases. The company's flagship product, PredictSURE IBD, is a diagnostic tool that evaluates patients with inflammatory bowel disease, including Crohn's disease and ulcerative colitis. This test utilizes a small blood sample to identify patients at diagnosis who are at risk of severe, relapsing disease, thereby enabling healthcare providers to recommend early biologic therapy to those who would benefit most. By providing crucial prognostic information, PredictImmune aims to enhance treatment decision-making for physicians and improve outcomes for patients suffering from these conditions. The company's research is rooted in leading studies from Cambridge University, reflecting its commitment to advancing personalized medicine in the field of inflammatory bowel disease.

DoorDash, Inc. is a logistics platform founded in 2013 and headquartered in San Francisco, California. It connects merchants, consumers, and delivery personnel, primarily in the United States, but has expanded its services to Europe through the acquisition of Wolt in 2022. The company operates a marketplace that allows merchants, including restaurants, grocery stores, and retailers, to reach customers by offering food and other goods for pickup or delivery. DoorDash provides a range of services to help merchants address critical challenges, including customer acquisition, payment processing, and customer support, while also offering a white-label logistics service called DoorDash Drive. The company aims to enhance local economies by facilitating connections between consumers and their favorite businesses.

CorInnova Incorporated provides device-based therapies for the treatment of congestive heart failure. CorInnova’s non-blood-contacting soft robotic cardiac assist device could potentially triple or quadruple the number of heart failure patients who could be eligible for such a life-saving device therapy.”

Exonate is a privately held, early stage, biotech company spun out of the University of Nottingham that is focused on alternative splicing of Vascular Endothelial Growth Factor (VEGF) in ophthalmology. Exonate’s lead programme is focused on Diabetic Macular Oedema (DMO). A consequence of diabetic retinopathy, DMO, is swelling in an area of the retina called the macula and wet Age-Related Macular Degeneration (wAMD), which is the leading cause of vision loss in people aged 60 and older. The Company is founded on scientific excellence with strong links to Professor David Bates and his lab at Nottingham University specializing in the biology and biochemical pathways of VEGF splice variants. Exonate have developed small molecules that inhibit production of pro-angiogenic VEGF through selective inhibition of serine/threonine-protein kinase 1 (SRPK1)-mediated VEGF splicing. These inhibitors have already demonstrated superior efficacy as topical agents in preclinical models of wet AMD. Through a Wellcome Trust funded project, Exonate has completed an optimization programme and has nominated a pre-clinical candidate drug with optimal characteristics. During the second quarter of 2020 regulatory toxicology and safety pharmacology studies have taken place. This is to support the successful application to the regulatory authorities for clinical evaluation. Exonate is led by an experienced, international management team that has previously worked together with cross-disciplinary experience in medicine and drug development, as well as successful fundraising for early stage companies. About Diabetic Macular Oedema (DMO)*: DMO is the build-up of fluid (Oedema) in a region of the retina called the macula. The macula is important for the sharp, straight-ahead vision that is used for reading, recognizing faces, and driving. DMO is the most common cause of vision loss among people with diabetic retinopathy. About half of all people with diabetic retinopathy will develop DMO and although it is more likely to occur as diabetic retinopathy worsens, DMO can happen at any stage of the disease. About wet Age-Related Macular Degeneration (wet AMD): Today, wet AMD is a leading cause of vision loss in people aged 60 years or older and affects more than 30 million patients worldwide, over 200,000 of those in the UK alone. If untreated patients are likely to lose sight in the affected eye within 24 months of disease onset. The main currently available treatment options for DMO and wet AMD are: • anti-VEGF antibody drugs – to prevent the growth of new blood vessels in the eye. Unlike small molecule drugs or eye drops these treatments must be injected into the eye once every 1 or 2 months. Resistance can develop to these drugs causing the disease to progress anew. • Laser surgery – to destroy abnormal blood vessels in the eye. This type of surgery is only suitable if blood vessel damage is not too extensive and if the abnormal blood vessels aren't close to the fovea, as performing surgery close to this part of the eye can cause permanent vision loss. • With DMO, Corticosteroids either injected or implanted into the eye, may be used alone or in combination with other drugs or laser surgery to treat DMO. *source: https://nei.nih.gov/health/diabetic/retinopathy

Kymab Limited is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, focused on discovering and developing fully human monoclonal antibody therapeutics. The company utilizes its proprietary Kymouse platform, which is part of the broader IntelliSelect® integrated platforms, to target difficult and novel drug challenges in various therapeutic areas, including immuno-oncology and immune-mediated diseases. Kymab’s technology allows for the generation of a diverse range of human antibodies, enhancing the potential for novel therapies in treating conditions such as cancer and autoimmune disorders. The company has established strategic collaborations, including partnerships with Heptares Therapeutics and LifeArc, to further its research and development efforts. Founded in 2009, Kymab Limited operates as a subsidiary of Kymab Group Limited.

Acesion Pharma ApS is a biotech company based in Copenhagen, Denmark, founded in 2011. The company specializes in the development of medical drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. Acesion Pharma focuses on creating SK channel inhibitors, which target specific ion channels in heart cells that are essential for generating the electrical signals that regulate heart rhythm. By inhibiting these channels, the company aims to provide safe and tolerable chronic treatments that prevent the recurrence of AF and support the maintenance of a normal heart rhythm.

Phononic is a growth stage, semiconductor hardware company commercializing solid-state heat pumps and fully integrated systems that displace compressors, heat sinks, and fans for electronics cooling; residential and commercial refrigeration; and climate control. The company’s disruptive approach combines high-performance solid-state heat pumps integrated into a manufacturing-friendly systems architecture that realizes products that are smart, sustainable, and solid state-driven.

Pearl is dedicated to bringing the latest advanced driver assistance features to all drivers on the road today. Products created by the team at Pearl leverage the very same technologies that are the building blocks of the autonomous vehicle. By deploying these features in the aftermarket, Pearl enables more consumers to have access to these key technologies.

DoorDash, Inc. is a logistics platform founded in 2013 and headquartered in San Francisco, California. It connects merchants, consumers, and delivery personnel, primarily in the United States, but has expanded its services to Europe through the acquisition of Wolt in 2022. The company operates a marketplace that allows merchants, including restaurants, grocery stores, and retailers, to reach customers by offering food and other goods for pickup or delivery. DoorDash provides a range of services to help merchants address critical challenges, including customer acquisition, payment processing, and customer support, while also offering a white-label logistics service called DoorDash Drive. The company aims to enhance local economies by facilitating connections between consumers and their favorite businesses.

Quethera Limited is a gene therapy company based in Canterbury, United Kingdom, founded in 2013. The company specializes in developing innovative treatments for glaucoma and other ophthalmic diseases, particularly aimed at reducing progressive visual loss associated with these conditions. Quethera collaborates with leading experts in the field of glaucoma to design and conduct clinical trials that evaluate the efficacy and safety of its novel therapies, especially for patients who experience accelerated visual field loss. With a strong foundation in gene therapeutic design and development, Quethera is advancing its research pipeline from preclinical testing into clinical development, striving to enhance treatment options for patients suffering from common blinding eye diseases. As of August 2018, Quethera operates as a subsidiary of Astellas Pharma Inc.

Mucosis B.V. is a clinical stage Dutch biotechnology company developing innovative mucosal vaccines that can be applied needle-free via the nose or mouth. Mucosis’s lead product candidate is SynGEM:registered:, an intranasal vaccine to prevent respiratory syncytial virus infection. Mucosis' vaccines are based on the patented and validated Mimopath:registered: technology. This technology enables a more natural immune response as well as a broad base of protection as was seen in their proof-of-concept animal and human studies of their FluGEM:registered: vaccine candidate.

MediSieve Ltd. is a medical device company based in London, United Kingdom, focused on developing Magnetic Blood Filtration (MBF) technology to treat blood-borne diseases. Established in 2014, the company has created a blood filtration device that magnetically removes infected blood cells, enabling the treatment of conditions such as malaria, leukemia, and sepsis. The MBF system operates by circulating a patient’s blood through an external loop where targeted magnetic particles bind to disease-relevant targets. The blood then passes through a magnetic filter that captures these particles and bound targets, allowing the unaffected blood to be returned to the patient. MediSieve's innovative approach also aims to enhance the safety and efficacy of existing therapies while expanding the range of treatable diseases. The company operates from the Imperial Incubator in White City, London, where it has specialized laboratory facilities for product development and validation.

Elastagen is a clinical stage medical company focused on developing products derived from the human protein tropoelastin, which is essential for the elasticity and resilience of various tissues in the body, including skin and blood vessels. The company has created a synthetic version of elastin that mimics the natural protein found in humans. Its advanced product pipeline targets applications in skin rejuvenation, scar remodeling, and tissue repair. With injectable synthetic human elastin and chemically cross-linked tropoelastin for aesthetic uses, Elastagen aims to help patients maintain skin elasticity and suppleness. Founded after acquiring intellectual property rights to elastin technology developed by Professor Weiss at the University of Sydney, Elastagen has successfully secured funding from prominent life science venture capital firms and expanded its operations to include production in Europe and clinical activities in the UK.

Klarna Inc. is an e-commerce payment solutions platform that facilitates cashless transactions for both merchants and shoppers. Founded in 2005 and headquartered in Columbus, Ohio, with additional offices in New York City, Klarna operates as a subsidiary of Klarna Bank AB. The company provides a range of payment options, including direct payments, pay-after-delivery choices, and installment plans, enabling customers to select their preferred payment method. Known for its "buy now, pay later" model, Klarna offers interest-free financing for retail purchases, enhancing the shopping experience. Additionally, the Klarna app provides users with flexible payment options and cashback rewards, while the platform supports in-store, mobile, and online payments, along with services for deliveries and returns.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing novel treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating antibacterial resistance-breakers that can restore the efficacy of existing antibiotics. Its key innovation includes inhibitors of bacterial metalloenzymes, specifically Metallo ß-lactamases (MBLs), which are designed to be used in combination with carbapenems to address significant treatment gaps in drug-resistant nosocomial infections. Antabio aims to provide health professionals with effective medicinal products to combat life-threatening respiratory infections, including carbapenem-resistant pneumonia and chronic pulmonary diseases. The company has received recognition for its research efforts, including a Wellcome Trust Seeding Drug Discovery Award.

Nabriva Therapeutics plc is a biopharmaceutical company focused on developing and commercializing innovative anti-infective agents for treating serious infections. Its lead product candidate, XENLETA, is a semi-synthetic pleuromutilin antibiotic approved for the treatment of community-acquired bacterial pneumonia and is also being investigated for other indications, including acute bacterial skin infections and pediatric infections. Additionally, the company is developing CONTEPO, a potential first-in-class epoxide antibiotic aimed at complicated urinary tract infections. Nabriva has established an exclusive agreement with Merck & Co. to market and distribute SIVEXTRO, an antibiotic for treating acute bacterial skin and skin structure infections. Founded in 2005 and headquartered in Dublin, Ireland, Nabriva Therapeutics is dedicated to advancing its pipeline of anti-infective therapies.

DoorDash, Inc. is a logistics platform founded in 2013 and headquartered in San Francisco, California. It connects merchants, consumers, and delivery personnel, primarily in the United States, but has expanded its services to Europe through the acquisition of Wolt in 2022. The company operates a marketplace that allows merchants, including restaurants, grocery stores, and retailers, to reach customers by offering food and other goods for pickup or delivery. DoorDash provides a range of services to help merchants address critical challenges, including customer acquisition, payment processing, and customer support, while also offering a white-label logistics service called DoorDash Drive. The company aims to enhance local economies by facilitating connections between consumers and their favorite businesses.

Verne Global, Inc. is a provider of computing solutions specializing in colocation and high-performance computing (HPC)-as-a-Service. Founded in 2006 and based in Arlington, Virginia, the company operates an environmentally-friendly data center campus in Keflavik, Iceland, which has been operational since 2012. This 45-acre facility, built on the site of a former NATO Command Center, was designed to address the challenges of rising power costs and carbon emissions in the data center industry. By utilizing renewable energy sources, including geothermal and hydroelectric power, Verne Global offers a competitively priced, carbon-neutral energy solution. The strategic location of the campus allows global clients to benefit from affordable power while ensuring reliability, making it an appealing option for industries such as artificial intelligence, earth sciences, engineering, financial services, life sciences, and scientific research. Verne Global operates as a subsidiary of Verne Holdings ehf.

Phononic is a growth stage, semiconductor hardware company commercializing solid-state heat pumps and fully integrated systems that displace compressors, heat sinks, and fans for electronics cooling; residential and commercial refrigeration; and climate control. The company’s disruptive approach combines high-performance solid-state heat pumps integrated into a manufacturing-friendly systems architecture that realizes products that are smart, sustainable, and solid state-driven.

Omniox is a biopharmaceutical company developing new medicines for hypoxic diseases. Hypoxia, defined as insufficient levels of oxygen in tissues, is known to trigger or impact a range of serious illnesses and conditions including many cancers, cardiovascular diseases, and trauma. At the center of Omniox’ work is a protein-based platform technology (H-NOX), that is engineered to reverse hypoxic disease states by delivering oxygen or nitric oxide preferentially to hypoxic tissues.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, which are serious genetic disorders. Founded on scientific discoveries from the academic work of Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society, Orphazyme collaborates with leading academic institutions across Europe and the United States. The company is actively engaged in biopharmaceutical research and development, and it has entered into a strategic partnership with CombiGene AB to advance its objectives in this field.

The AirStrip Technologies platform securely delivers critical patient information, including virtual real-time waveform data, directly from hospital monitoring systems to a doctor or nurse's smart phone, laptop or desktop. The platform is completely reusable, scalable and data independent, and can be employed throughout the healthcare enterprise.

Kymab Limited is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, focused on discovering and developing fully human monoclonal antibody therapeutics. The company utilizes its proprietary Kymouse platform, which is part of the broader IntelliSelect® integrated platforms, to target difficult and novel drug challenges in various therapeutic areas, including immuno-oncology and immune-mediated diseases. Kymab’s technology allows for the generation of a diverse range of human antibodies, enhancing the potential for novel therapies in treating conditions such as cancer and autoimmune disorders. The company has established strategic collaborations, including partnerships with Heptares Therapeutics and LifeArc, to further its research and development efforts. Founded in 2009, Kymab Limited operates as a subsidiary of Kymab Group Limited.

Integrated Diagnostics Inc. specializes in the development of laboratory-based blood molecular diagnostic tools designed to assist physicians in the early detection of complex diseases through non-invasive blood tests. The company's flagship product, Xpresys Lung, provides objective information for assessing pulmonary nodules by monitoring multiple disease molecular markers simultaneously. Founded in 2005 and based in Seattle, Washington, Integrated Diagnostics aims to leverage emerging technologies to create a pipeline of innovative diagnostic products that facilitate the management of serious conditions such as cancer, diabetes, and Alzheimer's. The company operates under the principle that a systems view of disease, involving networks of proteins, genes, and other molecules, is essential for effective diagnosis and prognosis. Integrated Diagnostics is a subsidiary of Biodesix, Inc. and has established a strategic partnership with Agilent Technologies.

Acesion Pharma ApS is a biotech company based in Copenhagen, Denmark, founded in 2011. The company specializes in the development of medical drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. Acesion Pharma focuses on creating SK channel inhibitors, which target specific ion channels in heart cells that are essential for generating the electrical signals that regulate heart rhythm. By inhibiting these channels, the company aims to provide safe and tolerable chronic treatments that prevent the recurrence of AF and support the maintenance of a normal heart rhythm.

Biocartis SA is a molecular diagnostics company based in Lausanne, Switzerland, focused on developing a technology platform for the multiplexed detection of bio-analytes. Established in 2007, Biocartis integrates molecular and immunodiagnostics through its proprietary micro-technology platform. The company offers a range of diagnostic solutions, including the Idylla molecular diagnostic system, which serves oncology and infectious disease applications. Its product portfolio features assays for various mutations, such as EGFR, BRAF, and NRAS, as well as a respiratory panel. These products are designed to enhance clinical practice by facilitating the detection, quantification, and monitoring of bio-molecules associated with disease risk factors and treatment decisions. Biocartis primarily generates revenue through the sale of its diagnostic products.

Venatorx Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery and development of novel anti-infective agents aimed at treating multi-drug-resistant bacterial infections and challenging viral infections. Founded in 2010 and based in Malvern, Pennsylvania, the company specializes in developing antibacterial drugs to combat resistant infections commonly encountered in hospital and community settings, such as those caused by MRSA, Pseudomonas spp., and Salmonella spp. Venatorx employs innovative chemical approaches to create treatments that exhibit selective and potent activity against various resistant bacterial strains, thereby providing healthcare professionals with broader treatment options to address significant unmet medical needs.

Treventis Corporation specializes in developing small molecule drugs aimed at treating and preventing protein misfolding diseases, particularly focusing on tauopathies related to Alzheimer’s disease. The company employs a proprietary discovery engine called Common Conformational Morphology (CCM), which integrates advanced in silico modeling with extensive expertise in drug development across various biological systems. This innovative approach allows Treventis to identify druggable active sites in misfolded protein targets, facilitating the rational design of therapeutic compounds. The lead program is centered around anti-misfolding small molecules that target tau proteins, while additional CCM-driven initiatives are underway in oncology and other neurodegenerative disorders, highlighting the versatility of their technology platform. The drugs developed by Treventis aim to effectively neutralize misfolded proteins, potentially blocking the progression of amyloid toxicity and offering a treatment option for Alzheimer’s patients with minimal side effects.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, focused on developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, which is a significant contributor to osteoarthritis, affecting over 300 million individuals worldwide. The company's flagship product, FibroFix, is a hydrogel biomaterial designed to mimic human knee cartilage, offering solutions for repairing both meniscal and articular cartilage. FibroFix Meniscus and FibroFix Cartilage are specifically tailored to restore function and integrate seamlessly with the body's tissues, promoting rapid recovery and improved mobility. Orthox is preparing to enter clinical trials for its lead product and plans to expand the application of its technology to other joints, as well as explore advancements beyond orthopaedics. With the global biomaterials market projected to exceed $250 billion by 2025, Orthox is well-positioned to capitalize on the growing demand for innovative and effective solutions in joint health.

Trino Therapeutics is a drug discovery and early development company specializing in anti-inflammatory therapeutics. The firm is focused on creating drug candidates from a unique class of compounds based on indane dimers derived from a Taiwanese fern. Its lead candidate aims to be a first-in-class treatment for inflammatory bowel disease (IBD), targeting conditions such as ulcerative colitis and Crohn’s disease. Additionally, Trino's novel drug class exhibits broad anti-inflammatory potential, making it suitable for various applications in dermatology, pulmonary conditions, and autoimmune diseases.

Canbex Therapeutics, based in London, United Kingdom, focuses on developing peripherally-acting cannabinoid agonists aimed at treating spasticity associated with multiple sclerosis and other neurodegenerative disorders. Founded in 2005, the company is committed to addressing the debilitating symptoms of spasticity, which include involuntary muscle spasms and stiffness. Canbex's lead program seeks to enhance the quality of life for patients suffering from this challenging and incurable condition, with the aim of establishing a new standard in the management of spasticity.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing novel treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating antibacterial resistance-breakers that can restore the efficacy of existing antibiotics. Its key innovation includes inhibitors of bacterial metalloenzymes, specifically Metallo ß-lactamases (MBLs), which are designed to be used in combination with carbapenems to address significant treatment gaps in drug-resistant nosocomial infections. Antabio aims to provide health professionals with effective medicinal products to combat life-threatening respiratory infections, including carbapenem-resistant pneumonia and chronic pulmonary diseases. The company has received recognition for its research efforts, including a Wellcome Trust Seeding Drug Discovery Award.

Haemostatix Ltd., founded in 2003 and based in Nottingham, United Kingdom, specializes in developing a peptide-based platform technology aimed at addressing surgical bleeding and advancing tissue repair and regenerative medicine. The company originated as a spin-out from the University of Leicester and was co-founded by Sarah Middleton and Professor Alison Goodall. Its product pipeline includes PeproStat, a coagulant applied directly to wounds to effectively manage bleeding during surgical procedures. Haemostatix also focuses on creating various forms of hemostats, including liquid and transparent gel formulations, which enhance the speed and safety of bleeding control for healthcare professionals. As of May 2016, Haemostatix operates as a subsidiary of Ergomed plc.

Summit Therapeutics Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. The company focuses on treating Clostridium difficile infection (CDI), with its lead product candidate, ridinilazole, currently in Phase III clinical trials. In addition to ridinilazole, Summit Therapeutics is developing the DDS-01 series aimed at treating infections caused by Neisseria gonorrhoeae and the DDS-04 series for Enterobacteriaceae. The company operates primarily in the United States, Latin America, and Europe, with the intention of establishing new standards of care for patients while creating value for payors and healthcare providers. Founded in 2003, Summit Therapeutics is positioned to address critical needs in the field of infectious diseases.

The AirStrip Technologies platform securely delivers critical patient information, including virtual real-time waveform data, directly from hospital monitoring systems to a doctor or nurse's smart phone, laptop or desktop. The platform is completely reusable, scalable and data independent, and can be employed throughout the healthcare enterprise.

Siluria Technologies is a materials innovation company focused on addressing global challenges in the natural gas, chemicals, and fuel sectors. By leveraging advancements in nanotechnology, biotechnology, and chemical engineering, Siluria has created a platform that enables the efficient production of chemicals and fuels from natural gas, which is a more abundant and cost-effective resource than oil. The company's technology allows for the conversion of natural gas and low-value by-products into higher-value products, including liquid fuels such as gasoline, diesel, and jet fuel. Siluria's research and development teams are actively working towards commercializing their technology through partnerships with leading chemical and fuel companies, facilitating pilot-scale production to integrate their innovations into existing industry infrastructure.

Kuur Therapeutics Limited specializes in the development and commercialization of CAR-NKT cell immunotherapies aimed at treating various forms of cancer. The company has established a pipeline of innovative immune cell products, including KUR-501 for neuroblastoma, KUR-502 for hematological malignancies, and KUR-503 for liver cancer. Kuur Therapeutics focuses on creating off-the-shelf engineered CAR-NKT cell therapies, harnessing the unique capabilities of natural killer T cells combined with advanced CAR construct engineering. This approach aims to provide effective treatments for both solid and hematological tumors, thereby enhancing patient care. Established in 2005 and based in London, the company was previously known as Cell Medica Limited before rebranding in February 2020. Kuur Therapeutics is actively engaged in clinical trials to advance its CAR-NKT cell therapies.

Castlight is on a mission to make it as easy as humanly possible for people to navigate the healthcare system, and live happier, healthier, more productive lives. They as a leader in healthcare navigation, we provide a world-class digital platform with a team of clinical, and benefits experts to help members easily connect, and engage with the right programs and care, at the right time. Castlight partners with companies, and health plans to transform employee, and member benefits into one comprehensive health, and wellbeing experience to deliver better health outcomes, and maximize returns on healthcare investments.

Sapphire Energy, Inc. is a San Diego-based company that specializes in producing renewable solutions from algae, pioneering the Green Crude industry. Founded in 2007, the company utilizes sunlight, carbon dioxide, non-potable water, and non-arable land to cultivate algae in outdoor ponds. This biomass can be converted into high-value products, including oils, aquaculture feeds, animal feeds, and fuels, without relying on food crops or potable water. Sapphire Energy's innovative processes not only enhance and replace traditional petroleum-based products but also operate compatibly with existing infrastructure, offering a low carbon and scalable alternative to conventional biofuels. The company has established a research and development facility in Las Cruces, New Mexico, and is developing an Integrated Algal BioRefinery in Columbus, New Mexico, to further its mission of creating sustainable energy solutions.

Integrated Diagnostics Inc. specializes in the development of laboratory-based blood molecular diagnostic tools designed to assist physicians in the early detection of complex diseases through non-invasive blood tests. The company's flagship product, Xpresys Lung, provides objective information for assessing pulmonary nodules by monitoring multiple disease molecular markers simultaneously. Founded in 2005 and based in Seattle, Washington, Integrated Diagnostics aims to leverage emerging technologies to create a pipeline of innovative diagnostic products that facilitate the management of serious conditions such as cancer, diabetes, and Alzheimer's. The company operates under the principle that a systems view of disease, involving networks of proteins, genes, and other molecules, is essential for effective diagnosis and prognosis. Integrated Diagnostics is a subsidiary of Biodesix, Inc. and has established a strategic partnership with Agilent Technologies.

Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health. The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life. Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging. Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors.

Sapiens Steering Brain Stimulation GmbH is an emerging medical device company whose mission is to deliver superior solutions for deep brain stimulation (DBS) therapy. Sapiens' ambition is to provide a unique, high-resolution, and MRI- compatible DBS system that will improve patient comfort and therapeutic outcome, initially for patients with Parkinson's disease. Sapiens, with offices in Eindhoven, the Netherlands and Munich, Germany, is founded in 2011 as a spin-out of Royal Philips Electronics. Its steering brain stimulation (SBS) system and image-guided programming are based upon patented technologies.

Biocartis SA is a molecular diagnostics company based in Lausanne, Switzerland, focused on developing a technology platform for the multiplexed detection of bio-analytes. Established in 2007, Biocartis integrates molecular and immunodiagnostics through its proprietary micro-technology platform. The company offers a range of diagnostic solutions, including the Idylla molecular diagnostic system, which serves oncology and infectious disease applications. Its product portfolio features assays for various mutations, such as EGFR, BRAF, and NRAS, as well as a respiratory panel. These products are designed to enhance clinical practice by facilitating the detection, quantification, and monitoring of bio-molecules associated with disease risk factors and treatment decisions. Biocartis primarily generates revenue through the sale of its diagnostic products.

Siluria Technologies is a materials innovation company focused on addressing global challenges in the natural gas, chemicals, and fuel sectors. By leveraging advancements in nanotechnology, biotechnology, and chemical engineering, Siluria has created a platform that enables the efficient production of chemicals and fuels from natural gas, which is a more abundant and cost-effective resource than oil. The company's technology allows for the conversion of natural gas and low-value by-products into higher-value products, including liquid fuels such as gasoline, diesel, and jet fuel. Siluria's research and development teams are actively working towards commercializing their technology through partnerships with leading chemical and fuel companies, facilitating pilot-scale production to integrate their innovations into existing industry infrastructure.

Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health. The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life. Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging. Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors.

Canbex Therapeutics, based in London, United Kingdom, focuses on developing peripherally-acting cannabinoid agonists aimed at treating spasticity associated with multiple sclerosis and other neurodegenerative disorders. Founded in 2005, the company is committed to addressing the debilitating symptoms of spasticity, which include involuntary muscle spasms and stiffness. Canbex's lead program seeks to enhance the quality of life for patients suffering from this challenging and incurable condition, with the aim of establishing a new standard in the management of spasticity.

Beyond Oblivion is a music and technology company founded in 2008 by its CEO, Adam Kidron. Its principle shareholders are Wellcome Trust, News Corporation, Allen & Company, Intertrust Technologies Corporation, and Adam Kidron. Beyond Oblivion's first go-to-market product is boinc. boinc is a magnetic and social music service that distributes a vast legal music library from a cloud (supplied by majors, independents, and artists the world over), and embeds the right to download and PLAY IT ALL within devices like PCs, tablets, autos and smartphones. boinc replaces paid-download, paid subscription, and advertiser-supported services with an inexpensive one-time, lifetime-of-device usage fee - paying copyright owners a micro-royalty per play, no matter if the original file were legally or illegally downloaded.

Wonga.com provides small, short-term cash advances to UK consumers online. The company uses sophisticated risk and decisioning technology to make automated yet responsible lending decisions. Applicants can first determine the exact size and length of the cash advance required, using sliders on the Wonga home page, before submitting personal details online. Wonga offers cash deposits within minutes and loans are available up to £750, for between five and 30 days. Wonga's real-time and fully automated loan processing systems means more speed, convenience, and flexibility than a typical online lender, or indeed any traditional form of credit. The principle behind Wonga is that customers use the service on an occasional basis, in reaction to cash emergencies, rather than as an ongoing source of credit. In contrast to credit cards, traditional loans and bank overdrafts, the idea is that money is repaid quickly, thereby avoiding long-term debt. The alternative for many consumers might be an unauthorized overdraft, which can incur significant bank charges, bounced cheques, or a cash loan from friends or family. The company's technical innovation has been recognized by several award schemes such as Red Herring Europe 100 and the National Business Awards.

Haemostatix Ltd., founded in 2003 and based in Nottingham, United Kingdom, specializes in developing a peptide-based platform technology aimed at addressing surgical bleeding and advancing tissue repair and regenerative medicine. The company originated as a spin-out from the University of Leicester and was co-founded by Sarah Middleton and Professor Alison Goodall. Its product pipeline includes PeproStat, a coagulant applied directly to wounds to effectively manage bleeding during surgical procedures. Haemostatix also focuses on creating various forms of hemostats, including liquid and transparent gel formulations, which enhance the speed and safety of bleeding control for healthcare professionals. As of May 2016, Haemostatix operates as a subsidiary of Ergomed plc.

ProteinSimple, part of the Protein Platforms division of Bio-Techne, specializes in innovative protein analysis tools that assist researchers in understanding proteins and their roles in disease. The company offers a diverse range of products, including immunoassay systems for quantifying protein expression and systems designed to assess the structure and purity of protein-based therapeutics. Their nano-proteomic analysis systems focus on resolving protein analysis issues, enabling life science researchers to measure phosphor-protein signaling and activation in small biological samples. These tools allow for the quantification of phosphor-protein isoforms in various cell types, including primary and sorted stem cells, and facilitate the monitoring of drug actions in tissue sections and fine needle aspirates. ProteinSimple's solutions are vital for advancing research in the life sciences globally.

Kymab Limited is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, focused on discovering and developing fully human monoclonal antibody therapeutics. The company utilizes its proprietary Kymouse platform, which is part of the broader IntelliSelect® integrated platforms, to target difficult and novel drug challenges in various therapeutic areas, including immuno-oncology and immune-mediated diseases. Kymab’s technology allows for the generation of a diverse range of human antibodies, enhancing the potential for novel therapies in treating conditions such as cancer and autoimmune disorders. The company has established strategic collaborations, including partnerships with Heptares Therapeutics and LifeArc, to further its research and development efforts. Founded in 2009, Kymab Limited operates as a subsidiary of Kymab Group Limited.

Castlight is on a mission to make it as easy as humanly possible for people to navigate the healthcare system, and live happier, healthier, more productive lives. They as a leader in healthcare navigation, we provide a world-class digital platform with a team of clinical, and benefits experts to help members easily connect, and engage with the right programs and care, at the right time. Castlight partners with companies, and health plans to transform employee, and member benefits into one comprehensive health, and wellbeing experience to deliver better health outcomes, and maximize returns on healthcare investments.

Biota Holdings Limited is an Australian company focused on the discovery and development of anti-infective drugs, primarily targeting respiratory diseases such as influenza. The company is known for developing zanamivir, a neuraminidase inhibitor marketed as Relenza for seasonal influenza treatment. Biota's research efforts have also led to the creation of nucleoside analogues for hepatitis C virus infections, which have been licensed to Boehringer Ingelheim, along with candidates for respiratory syncytial virus treatment. Currently, Biota is conducting clinical trials for a lead compound aimed at human rhinovirus infections, particularly in patients with compromised respiratory or immune systems. The company has established a partnership with Daiichi Sankyo to develop second-generation influenza antivirals and has expanded its portfolio through the acquisition of antibacterial assets from MaxThera Inc.

Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. The company's most advanced drug candidate, ACHN-490, has demonstrated a positive safety and dosing profile in Phase 1 clinical testing and displayed broad spectrum efficacy in preclinical studies against systemic infections caused by multi-drug resistant (MDR) Gram-negative bacteria (e.g., E. coli, K. pneumoniae, and P. aeruginosa) and MRSA. In addition, the company is pursuing preclinical programs in several other areas of interest to combat the global emergence of bacterial resistance.

Mintaka Foundation is finding simple health solutions for developing countries using advanced technology.

Summit Therapeutics Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. The company focuses on treating Clostridium difficile infection (CDI), with its lead product candidate, ridinilazole, currently in Phase III clinical trials. In addition to ridinilazole, Summit Therapeutics is developing the DDS-01 series aimed at treating infections caused by Neisseria gonorrhoeae and the DDS-04 series for Enterobacteriaceae. The company operates primarily in the United States, Latin America, and Europe, with the intention of establishing new standards of care for patients while creating value for payors and healthcare providers. Founded in 2003, Summit Therapeutics is positioned to address critical needs in the field of infectious diseases.

Oxagen Limited is a biopharmaceutical company focused on developing and commercializing anti-inflammatory medications for asthma and other chronic allergic conditions. The company specializes in small molecule drugs, including OC000459, an oral CRTH2 antagonist aimed at treating eosinophilic asthma and allergic rhinoconjunctivitis. Oxagen's drug development targets the CRTH2 receptor, which plays a critical role in the initiation and maintenance of allergic responses. In addition to asthma, their pipeline includes treatments for autoimmune diseases, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Founded in 1996 and based in London, Oxagen serves customers in the United Kingdom, Russia, and other countries in the Commonwealth of Independent States.

Nabriva Therapeutics plc is a biopharmaceutical company focused on developing and commercializing innovative anti-infective agents for treating serious infections. Its lead product candidate, XENLETA, is a semi-synthetic pleuromutilin antibiotic approved for the treatment of community-acquired bacterial pneumonia and is also being investigated for other indications, including acute bacterial skin infections and pediatric infections. Additionally, the company is developing CONTEPO, a potential first-in-class epoxide antibiotic aimed at complicated urinary tract infections. Nabriva has established an exclusive agreement with Merck & Co. to market and distribute SIVEXTRO, an antibiotic for treating acute bacterial skin and skin structure infections. Founded in 2005 and headquartered in Dublin, Ireland, Nabriva Therapeutics is dedicated to advancing its pipeline of anti-infective therapies.

Integrated Diagnostics Inc. specializes in the development of laboratory-based blood molecular diagnostic tools designed to assist physicians in the early detection of complex diseases through non-invasive blood tests. The company's flagship product, Xpresys Lung, provides objective information for assessing pulmonary nodules by monitoring multiple disease molecular markers simultaneously. Founded in 2005 and based in Seattle, Washington, Integrated Diagnostics aims to leverage emerging technologies to create a pipeline of innovative diagnostic products that facilitate the management of serious conditions such as cancer, diabetes, and Alzheimer's. The company operates under the principle that a systems view of disease, involving networks of proteins, genes, and other molecules, is essential for effective diagnosis and prognosis. Integrated Diagnostics is a subsidiary of Biodesix, Inc. and has established a strategic partnership with Agilent Technologies.

Pacific Biosciences specializes in human, microbial, plant, and animal genomics, focusing on areas such as infectious disease research. The company designs and manufactures sequencing systems that address complex genetic challenges, utilizing its innovative single molecule real-time (SMRT) sequencing technology to detect biological processes in real time. Its product offerings include the PacBio RS II and Sequel Systems, which facilitate the monitoring and analysis of biochemical reactions at the single-molecule level, along with consumables like SMRT cells and various reagent kits. Customers range from research institutions and commercial laboratories to pharmaceutical and agricultural companies, with sales conducted through direct channels in North America and Europe, and distribution partners in Asia, the Middle East, and Latin America. Founded in 2000 and headquartered in Menlo Park, California, Pacific Biosciences continues to advance genomics research and applications.

Chroma Therapeutics is a privately-held biotechnology company focused on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. Chroma is the first company to systematically assemble intellectual property in chromatin biology and has established a strong network of academic collaborators. Chroma aims to build substantial shareholder value through the creation of a broad and innovative product pipeline aimed at the treatment of high-prevalence cancers and inflammatory disorders.

VaxInnate is a vaccine company that focuses on developing cures for flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. It specializes in the fields of healthcare, health diagnostics, and biotechnology. It was founded in 2002 and headquartered in Cranbury, New Jersey.

Azellon is focused on developing stem cell therapy for the repair of avascular meniscal tears. Today orthopaedic surgeons are partially or fully removing the meniscus which over 4-6 years will lead to osteoarthritic changes in the knee joint. The technology behind Azellon was developed by Professor Anthony Hollander over the last 5 years and has already been proven highly successful in an in-vitro model.

ProteinSimple, part of the Protein Platforms division of Bio-Techne, specializes in innovative protein analysis tools that assist researchers in understanding proteins and their roles in disease. The company offers a diverse range of products, including immunoassay systems for quantifying protein expression and systems designed to assess the structure and purity of protein-based therapeutics. Their nano-proteomic analysis systems focus on resolving protein analysis issues, enabling life science researchers to measure phosphor-protein signaling and activation in small biological samples. These tools allow for the quantification of phosphor-protein isoforms in various cell types, including primary and sorted stem cells, and facilitate the monitoring of drug actions in tissue sections and fine needle aspirates. ProteinSimple's solutions are vital for advancing research in the life sciences globally.

Phico Therapeutics Limited is a biotechnology company based in Bourn, United Kingdom, focused on developing innovative antibiotics to combat antibacterial resistance. Utilizing its SASPject platform, the company delivers anti-bacterial proteins, including small acid-soluble spore proteins, to specific bacterial species through targeted non-delivery vehicles. Phico's product pipeline includes SASPject PT3, an antibiotic aimed at Pseudomonas aeruginosa; SASPject PT4 and PT5, designed for systemic use against Klebsiella pneumonia and Escherichia coli; and SASPject PT1.2, which targets Staphylococcus aureus. Additionally, the company is developing an intravenous-engineered bacteriophage drug intended to treat ventilator-associated pneumonia by using engineered bacterial viruses along with antibacterial proteins to inhibit bacterial reproduction and toxin release. Founded in 2000, Phico Therapeutics is committed to advancing solutions for pressing healthcare challenges posed by antibiotic resistance.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, focused on developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, which is a significant contributor to osteoarthritis, affecting over 300 million individuals worldwide. The company's flagship product, FibroFix, is a hydrogel biomaterial designed to mimic human knee cartilage, offering solutions for repairing both meniscal and articular cartilage. FibroFix Meniscus and FibroFix Cartilage are specifically tailored to restore function and integrate seamlessly with the body's tissues, promoting rapid recovery and improved mobility. Orthox is preparing to enter clinical trials for its lead product and plans to expand the application of its technology to other joints, as well as explore advancements beyond orthopaedics. With the global biomaterials market projected to exceed $250 billion by 2025, Orthox is well-positioned to capitalize on the growing demand for innovative and effective solutions in joint health.

Qwell's goal is to develop a new family of small-molecule drugs, derived from a plant source, that have a potent ability to fight tumors and excess inflammation of skin cells.

Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health. The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life. Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging. Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors.

Sapphire Energy, Inc. is a San Diego-based company that specializes in producing renewable solutions from algae, pioneering the Green Crude industry. Founded in 2007, the company utilizes sunlight, carbon dioxide, non-potable water, and non-arable land to cultivate algae in outdoor ponds. This biomass can be converted into high-value products, including oils, aquaculture feeds, animal feeds, and fuels, without relying on food crops or potable water. Sapphire Energy's innovative processes not only enhance and replace traditional petroleum-based products but also operate compatibly with existing infrastructure, offering a low carbon and scalable alternative to conventional biofuels. The company has established a research and development facility in Las Cruces, New Mexico, and is developing an Integrated Algal BioRefinery in Columbus, New Mexico, to further its mission of creating sustainable energy solutions.

Senexis is operates as a small-molecule drug discovery company, engages in discovering compounds for the treatment of ageing-related diseases resulting from the toxicity of amyloid-like proteins. The company offers small molecule inhibitors of amyloid aggregation and toxicity as therapeutic agents to inhibit the pathogenic process of protein misfolding, amyloid-related toxicity, and inflammation.

Endotis discovers, develops, and manufactures cardiovascular therapeutics. The company also discovers and develops small-glyco drugs for applications in thrombosis, oncology, and hematology areas. Its portfolio of products includes EP217609, a neutralizable anti-coagulant for managing extracorporeal blood circulation during open-heart surgery; FondaParinux, an injectable drug for the prevention and treatment of venous thromboembolism; and an oral anti-coagulant for stroke prevention in atrial fibrillation. Endotis was founded in 2003 and is based in Romainville, France.

Leveraging the extensive knowledge of GSK's Biotransformation and Natural Products scientific team, Novacta Biosystems Ltd was founded in 2003. In the following 5 years, Novacta successfully adopted a dual business model, whereby it developed a biocatalysis and microbial pathway engineering service business, that supported its efforts to build an infectious disease therapeutic pipeline.

Fovea Pharmaceuticals is a French biopharmaceutical company. It discovers and develops drugs for the treatment of ocular diseases. The company offers FOV1101 Prednisporin for the treatment of allergic conjunctivitis; FOV2302, a proprietary plasma kallikrein-kinin inhibitor for the systemic treatment of hereditary angioedema; FOV2304 for the treatment of diabetic macular edema; and FOV2501, an intravitreal formulation of RdCVF designed to treat retinitis pigmentosa with extension to dry age-related macular degeneration. Fovea Pharmaceuticals was founded in 2005 and is based in Paris, France. As of October 30, 2009, it operates as a subsidiary of Sanofi.

Sentinel Oncology Limited is a drug discovery company based in Cambridge, United Kingdom, founded in 2005. The company focuses on developing and commercializing therapeutics aimed at treating cancer, particularly for patients facing unmet medical needs. Sentinel Oncology's research and development pipeline includes innovative programs such as a treatment targeting Checkpoint Kinase 1, which is activated in response to DNA damage and replication stress, and a novel approach to treating metastatic breast cancer through the inhibition of S6K1. The company is advancing a strategy known as "Targeted Synergy," designed to enhance the therapeutic index by delivering drug effects directly to tumors. By fostering partnerships with the biotechnology and pharmaceutical industries, Sentinel Oncology aims to maximize the value of its drug candidates and contribute to improved cancer treatments.

Lectus Therapeutics Limited is a UK-based pharmaceutical company. Its mission is to build a development pipeline containing first-in-class ion channel therapeutics identified through the use of its proprietary proteomics technology for pain management and the treatment of urinary bladder disorders.

Xtera is a privately held network equipment and services company, and a leading provider of optical networks for terrestrial and subsea applications. Over the last year Xtera has succeeded in expanding its customer base and product portfolio in both existing and new markets. The AscenVision acquisition continues this strategic growth, extending Xtera's product portfolio beyond the optical layer. Xtera supplies both un-repeatered and repeatered systems, using our high-performance optical amplifiers to deliver traffic directly inland to cities. They create novel solutions that are tailored to each individual customer, whether providing a full turnkey system, an open architecture design, or a supply of a particular product or service.

Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health. The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life. Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging. Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors.

Kuur Therapeutics Limited specializes in the development and commercialization of CAR-NKT cell immunotherapies aimed at treating various forms of cancer. The company has established a pipeline of innovative immune cell products, including KUR-501 for neuroblastoma, KUR-502 for hematological malignancies, and KUR-503 for liver cancer. Kuur Therapeutics focuses on creating off-the-shelf engineered CAR-NKT cell therapies, harnessing the unique capabilities of natural killer T cells combined with advanced CAR construct engineering. This approach aims to provide effective treatments for both solid and hematological tumors, thereby enhancing patient care. Established in 2005 and based in London, the company was previously known as Cell Medica Limited before rebranding in February 2020. Kuur Therapeutics is actively engaged in clinical trials to advance its CAR-NKT cell therapies.